Skip to main content

Table 1 Baseline characteristics of patients

From: Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults

 

ABC/3TC/RPV (n = 66) (%)

ABC/3TC/EFV or boosted PIs (n = 104) (%)

p-value

Age, years, median (IQR)

35 (28–46)

30 (30–49)

0.04

Male

63 (95.4)

95 (91.3)

0.37

Race

  

0.40

 Chinese

45 (68.2)

73 (70.2)

 

 Malay

16 (24.2)

21 (20.2)

 Indian

5 (7.5)

5 (4.8)

 Others

0 (0)

5 (4.8)

HIV transmission route

  

0.20

 Homosexual

42 (63.6)

54 (52)

 

 Heterosexual

12 (18.2)

30 (28.9)

 Bisexual

8 (12.1)

18 (17.3)

 IVDU + sexual contact

2 (3.0)

1 (1.1)

 Others

2 (3.0)

1 (1)

Baseline viral load (copies/ml)

  

0.42

 < 10,000

21 (31.8)

24 (23.1)

 

 10,000–50,000

34 (51.5)

58 (55.8)

 > 50,000

11 (16.7)

22 (21.2)

Baseline CD4 count

  

0.37

 200–350

21 (31.8)

44 (42.3)

 

 > 350–500

21 (31.8)

30 (28.8)

 > 500

24 (36.4)

30 (28.8)

AIDS defining illness

0 (0)

0 (0)

NA

HCV co-infection

2 (3.0)

3 (2.9)

0.95

Genotype test at diagnosis

29 (44.0)

55 (52.9)

0.26

Time from diagnosis to treatment, days, median (IQR)

67 (45–215)

84 (48–351)

0.27

HLA B*5701

  

<0.01

 Positive

0 (0)

1 (1.0)

 

 Negative

61 (92.4)

65 (62.5)

 Not done

5 (7.6)

38 (36.5)

Comorbidities

   

 Diabetes mellitus

5 (7.5)

6 (5.8)

0.64

 Hypertension

7 (10.6)

9 (8.6)

0.67

 Hyperlipidemia

5 (7.6)

9 (8.7)

0.80

 IHD/CAD

1 (1.5)

2 (1.9)

0.84

 Congestive cardiac failure

0 (0)

0 (0)

NA

 Chronic liver disease

0 (0)

0 (0)

NA

 Chronic kidney disease

0 (0)

3 (2.9)

0.16

 Cancer

0 (0)

1 (1)

0.42

 CVA

0 (0)

0 (0)

NA

 Osteoporosis

0 (0)

0 (0)

NA

  1. ABC abacavir, 3TC lamivudine, RPV rilpivirine, IQR interquartile range, IVDU intravenous drug use, AIDS acquired immunodeficiency syndrome, HCV hepatitis C Virus, IHD ischaemic heart disease, CAD coronary artery disease, CVA cerebrovascular accident